PharmaShots | Incisive News in 3 Shots

Subscribe Now

Non-Small Cell Lung Cancer (NSCLC)

AstraZeneca's Imfinzi (durvalumab) New Dosing Option Receives Approval for NSCLC in the EU & UK

AstraZeneca's Imfinzi (durvalumab) New Dosing Option Receives Approval for NSCLC in the EU & UK

January 18, 2021

AstraZeneca Reports Results of Imfinzi (durvalumab) & Tremelimumab in Global P-III MYSTIC Trial for Stage IV Non-Small Cell Lung Cancer (NSCLC)

AstraZeneca Reports Results of Imfinzi (durvalumab) & Tremelimumab in Global P-III MYSTIC Trial for Stage IV Non-Small Cell Lu...

November 19, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us